Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Grants and Contracts Details

StatusActive
Effective start/end date2/4/206/2/23

Funding

  • Merck Sharp & Dohme Corporation: $23,451.00